Chan, A.-W.,
Hróbjartsson, A.,
Haahr, M. T.,
Gøtzsche, P. C., and
Altman, D. G.,
“Empirical Evidence for Selective Reporting of Outcomes in Randomized Trials: Comparison of Protocols to Published Articles,” JAMA 291, no.
20 (
2004):
2457–
2465;
Coyne, D. W., “The Health-Related Quality of Life Was Not Improved by Targeting Higher Hemoglobin in the Normal Hematocrit Trial,”
Kidney International 82, no. 2 (2012): 235–241;
Dwan, K.,
Gamble, C.,
Williamson, P. R., and
Kirkham, J. J., “Reporting Bias Group. Systematic Review of the Empirical Evidence of Study Publication Bias and Outcome Reporting Bias: An Updated Review,”
PLoS One 8, no. 7 (2013): e66844;
Eyding, D.,
Lelgemann, M.,
Grouven, U.,
Härter, M.,
Kromp, M.,
Kaiser, T.,
et al., “Reboxetine for Acute Treatment of Major Depression: Systematic Review and Meta-analysis of Published and Unpublished Placebo and Selective Serotonin Reuptake Inhibitor Controlled Trials,”
BMJ 341 (2010): c4737;
Fu, R.,
Selph, S.,
McDonagh, M.,
Peterson, K.,
Tiwari, A.,
Chou, R.,
et al., “Effectiveness and Harms of Recombinant Human Bone Morphogenetic Protein-2 in Spine Fusion: A Systematic Review and Meta-analysis,”
Annals of Internal Medicine 158, no. 12 (2013): 890–902;
Golder, S.,
Loke, Y. K.,
Wright, K., and
Norman, G., “Reporting of Adverse Events in Published and Unpublished Studies of Health Care Interventions: A Systematic Review,”
PLoS Medicine 13, no. 9 (2016): e1002127;
Hughes, S.,
Cohen, D., and
Jaggi, R., “Differences in Reporting Serious Adverse Events in Industry Sponsored Clinical Trial Registries and Journal Articles on Antidepressant and Antipsychotic Drugs: A Cross-Sectional Study,”
BMJ Open 4, no. 7 (2014): e005535;
Huić, M.,
Marušić, M., and
Marušić, A., “Completeness and Changes in Registered Data and Reporting Bias of Randomized Controlled Trials in ICMJE Journals after Trial Registration Policy,”
PLoS One 6, no. 9 (2011): e25258;
Jefferson, T.,
Doshi, P.,
Thompson, M., and
Heneghan, C., “Ensuring Safe and Effective Drugs: Who Can Do What It Takes?”
BMJ 342 (2011): c7258;
Jefferson, T.,
Jones, M. A.,
Doshi, P.,
Del Mar, C. B.,
Heneghan, C. J.,
Hama, R.,
et al., “Neuraminidase Inhibitors for Preventing and Treating Influenza in Healthy Adults and Children,”
Cochrane Database of Systematic Reviews 1 (2012): CD008965;
Köhler, M.,
Haag, S.,
Biester, K.,
Brockhaus, A. C.,
McGauran, N.,
Grouven, U.,
et al., “Information on New Drugs at Market Entry: Retrospective Analysis of Health Technology Assessment Reports Versus Regulatory Reports, Journal Publications, and Registry Reports,”
BMJ 350 (2015): h796;
Le Noury, J.,
Nardo, J. M.,
Healy, D.,
Jureidini, J.,
Raven, M.,
Tufanaru, C.,
et al., “Restoring Study 329: Efficacy and Harms of Paroxetine and Imipramine in Treatment of Major Depression in Adolescence,”
BMJ 351 (2015): h4320;
Lundh, A.,
Lexchin, J.,
Mintzes, B.,
Schroll, J. B., and
Bero, L., “Industry Sponsorship and Research Outcome,”
Cochrane Database of Systematic Reviews 2 (2017): MR000033;
Maund, E.,
Tendal, B.,
Hróbjartsson, A.,
Jørgensen, K. J.,
Lundh, A.,
Schroll, J.,
et al., “Benefits and Harms in Clinical Trials of Duloxetine for Treatment of Major Depressive Disorder: Comparison of Clinical Study Reports, Trial Registries, and Publications,”
BMJ 348 (2014): g3510;
McGauran, N.,
Wieseler, B.,
Kreis, J.,
Schüler, Y.-B.,
Kölsch, H., “Kaiser T. Reporting Bias in Medical Research: A Narrative Review,”
Trials 11 (2010): 37;
Rodgers, M. A.,
Brown, J. V. E.,
Heirs, M. K.,
Higgins, J. P. T.,
Mannion, R. J.,
Simmonds, M. C.,
et al., “Reporting of Industry Funded Study Outcome Data: Comparison of Confidential and Published Data on the Safety and Effectiveness of rhBMP-2 for Spinal Fusion,”
BMJ 346 (2013): f3981;
Saini, P.,
Loke, Y. K.,
Gamble, C.,
Altman, D. G.,
Williamson, P. R., and
Kirkham, J. J., “Selective Reporting Bias of Harm Outcomes within Studies: Findings from a Cohort of Systematic Reviews,”
BMJ 349 (2014): g6501;
Song, F.,
Parekh, S.,
Hooper, L.,
Loke, Y.K.,
Ryder, J.,
Sutton, A. J.,
et al., “Dissemination and Publication of Research Findings: An Updated Review of Related Biases,”
Health Technology Assessment 14, no. 8 (2010): iii, ix-xi, 1–193;
Turner, E. H.,
Matthews, A. M.,
Linardatos, E.,
Tell, R. A., and
Rosenthal, R., “Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy,”
New England Journal of Medicine 358, no. 3 (2008): 252–260;
Vedula, S. S.,
Li, T., and
Dickersin, K., “Differences in Reporting of Analyses in Internal Company Documents Versus Published Trial Reports: Comparisons in Industry-Sponsored Trials in Off-Label Uses of Gabapentin,”
PLoS Medicine 10, no. 1 (2013): e1001378;
Vedula, S. S.,
Bero, L.,
Scherer, R. W., and
Dickersin, K., “Outcome Reporting in Industry-Sponsored Trials of Gabapentin for Off-Label Use,”
New England Journal of Medicine 361, no. 20 (2009): 1963–1971;
Wieseler, B.,
Kerekes, M. F.,
Vervoelgyi, V.,
McGauran, N., and
Kaiser, T., “Impact of Document Type on Reporting Quality of Clinical Drug Trials: A Comparison of Registry Reports, Clinical Study Reports, and Journal Publications,”
BMJ 344 (2012): d8141;
Wieseler, B.,
Wolfram, N.,
McGauran, N.,
Kerekes, M. F.,
Vervölgyi, V.,
Kohlepp, P.,
et al., “Completeness of Reporting of Patient-Relevant Clinical Trial Outcomes: Comparison of Unpublished Clinical Study Reports with Publicly Available Data,”
PLoS Medicine 10, no. 10 (2013): e1001526;
Yank, V.,
Rennie, D., and
Bero, L. A., “Financial Ties and Concordance between Results and Conclusions in Meta-analyses: Retrospective Cohort Study,”
BMJ 335, no. 7631 (2007): 1202–1205;
Vedula, S. S.,
Goldman, P. S.,
Rona, I. J.,
Greene, T. M., and
Dickersin, K., “Implementation of a Publication Strategy in the Context of Reporting Biase: A Case Study Based on New Documents from Neurontin Litigation,”
Trials 13 (2012):136.
CrossRefGoogle Scholar 
